Company profile: Evonetix
1.1 - Company Overview
Company description
- Provider of a benchtop platform that synthesizes, assembles, and error-corrects gene-length DNA on a silicon chip with unprecedented accuracy and scale using thermal control of DNA synthesis. Offers chip technology to synthesize thousands of oligonucleotide sequences simultaneously, binary assembly, and thermal error removal for rapid, precise gene synthesis.
Products and services
- Evaleo: A custom-engineered benchtop device that synthesizes gene-length DNA by integrating oligonucleotide synthesis, on-chip assembly, and error correction on a single silicon chip
- Novel Chip Technology: Silicon-based DNA synthesis chips fabricate thousands of independent oligonucleotide sequences simultaneously under precise thermal control, enabling parallel, high-scale strand generation
- Thermal Control of DNA Synthesis: A phosphoramidite-based method re-engineers chemistry to control oligonucleotide extension through precise thermal regulation, enhancing DNA synthesis precision during on-chip synthesis.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Evonetix
Lexogen
HQ: Austria
Website
- Description: Provider of next-generation sequencing and transcriptomics solutions, offering whole transcriptome sequencing, small RNA sequencing, and gene expression analysis services, plus SIRVs (Spike-in RNA Variant Control Mixes) for validation and Mix² RNA-Seq data analysis software.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexogen company profile →
Verogen
HQ: United States
Website
- Description: Provider of tailored next-generation sequencing solutions for forensic laboratories, including the MiSeq FGx Sequencing System (Forensic Genomics and Research Use Only modes); ForenSeq DNA Signature Prep, MainstAY, Kintelligence, and Imagen kits for human identification, kinship, and phenotypic/biogeographical ancestry; and Universal Analysis Software for data management, high-volume analysis, and reporting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verogen company profile →
Devyser
HQ: Sweden
Website
- Description: Provider of diagnostic kits for complex DNA testing in oncology, hereditary diseases, and transplantation, used to guide targeted cancer therapies and enable genetic testing. Sold in 60+ countries, offerings include NGS-based tests for thalassemia, cystic fibrosis, familial hypercholesterolemia, thrombophilia, HFE mutations, and Y-chromosome microdeletions linked to male infertility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Devyser company profile →
NeoPhore
HQ: United Kingdom
Website
- Description: Provider of novel small molecule cancer therapies that stimulate the immune system by targeting DNA mismatch repair to induce neoantigen expression and increase immunogenicity in solid tumors, including PMS2 and MLH1 modulators that convert immune-cold tumors to hot and enhance sensitivity to immune checkpoint inhibitors, plus continuous neoantigen creation and research and development on next-generation targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoPhore company profile →
Prime Medicine
HQ: United States
Website
- Description: Provider of gene editing technologies and therapies utilizing Prime Editing to modify genetic sequences to treat a wide range of diseases. Offerings include Prime Editors for precise edits across tissues and cell types, Dual Flap Prime Editing for broader edits, PASSIGE for inserting large gene-sized sequences, and Prime-Edited Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prime Medicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Evonetix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Evonetix
2.2 - Growth funds investing in similar companies to Evonetix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Evonetix
4.2 - Public trading comparable groups for Evonetix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →